Literature DB >> 29523682

The length of the interleukin-11 receptor stalk determines its capacity for classic signaling.

Juliane Lokau1, Christoph Garbers2.   

Abstract

Interleukin (IL)-11 is a multifunctional cytokine that was traditionally recognized for its hematopoietic and anti-inflammatory functions, but has recently been shown also to be involved in tumorigenesis. IL-11 signaling is initiated by binding of the cytokine to the IL-11 receptor (IL-11R), which is not directly involved in signaling but required for IL-11 binding to the signal-transducing receptor glycoprotein (gp) 130. In classic signaling, IL-11 binds to the membrane-bound IL-11R to initiate signal transduction. Additionally, IL-11 signaling can be initiated via soluble IL-11R, known as trans-signaling, and this pathway only requires the three extracellular domains of the IL-11R, but not stalk, transmembrane, or intracellular region. Here, we analyzed the role of the IL-11R stalk region, a 55 amino acid stretch connecting the extracellular domains with the transmembrane helix, in classic IL-11 signaling with the help of cytokine-dependent cell lines. We showed that the stalk region is crucial for IL-11 signaling via the membrane-bound IL-11R. Using different deletion variants, we found that a minimal length of 23 amino acid residues is required for efficient signal transduction. We further found that classic IL-11 signaling depended solely on the length, but not the sequence, of the IL-11R stalk region, suggesting that the stalk functions as a spacer in the signaling complex. We previously described the IL-11R stalk region as determinant of proteolysis and regulator of IL-11 trans-signaling. The results presented here reveal an additional function in classic IL-11 signaling, highlighting the importance of the IL-11R stalk in IL-11 signaling.
© 2018 Lokau and Garbers.

Entities:  

Keywords:  STAT3; cytokine; gp130; interleukin; interleukin-11; interleukin-11 receptor; proliferation; signal transduction; stalk region

Mesh:

Substances:

Year:  2018        PMID: 29523682      PMCID: PMC5925790          DOI: 10.1074/jbc.RA118.001879

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Plasticity and cross-talk of interleukin 6-type cytokines.

Authors:  Christoph Garbers; Heike M Hermanns; Fred Schaper; Gerhard Müller-Newen; Joachim Grötzinger; Stefan Rose-John; Jürgen Scheller
Journal:  Cytokine Growth Factor Rev       Date:  2012-05-15       Impact factor: 7.638

2.  Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M.

Authors:  Z J Gu; J Wijdenes; X G Zhang; M M Hallet; C Clement; B Klein
Journal:  J Immunol Methods       Date:  1996-03-28       Impact factor: 2.303

Review 3.  Interleukin-6 signalling: more than Jaks and STATs.

Authors:  René Eulenfeld; Anna Dittrich; Christina Khouri; Pia J Müller; Barbara Mütze; Alexandra Wolf; Fred Schaper
Journal:  Eur J Cell Biol       Date:  2011-12-03       Impact factor: 4.492

4.  A gp130-Src-YAP module links inflammation to epithelial regeneration.

Authors:  Koji Taniguchi; Li-Wha Wu; Sergei I Grivennikov; Petrus R de Jong; Ian Lian; Fa-Xing Yu; Kepeng Wang; Samuel B Ho; Brigid S Boland; John T Chang; William J Sandborn; Gary Hardiman; Eyal Raz; Yoshihiko Maehara; Akihiko Yoshimura; Jessica Zucman-Rossi; Kun-Liang Guan; Michael Karin
Journal:  Nature       Date:  2015-02-25       Impact factor: 49.962

5.  Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells.

Authors:  H Baumann; Y Wang; K K Morella; C F Lai; H Dams; D J Hilton; R G Hawley; A Mackiewicz
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

6.  Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.

Authors:  Paul Baran; Rebecca Nitz; Joachim Grötzinger; Jürgen Scheller; Christoph Garbers
Journal:  J Biol Chem       Date:  2013-04-05       Impact factor: 5.157

7.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

Authors:  Tracy L Putoczki; Stefan Thiem; Andrea Loving; Rita A Busuttil; Nicholas J Wilson; Paul K Ziegler; Paul M Nguyen; Adele Preaudet; Ryan Farid; Kirsten M Edwards; Yeliz Boglev; Rodney B Luwor; Andrew Jarnicki; David Horst; Alex Boussioutas; Joan K Heath; Oliver M Sieber; Irina Pleines; Benjamin T Kile; Andrew Nash; Florian R Greten; Brent S McKenzie; Matthias Ernst
Journal:  Cancer Cell       Date:  2013-08-12       Impact factor: 31.743

8.  Modular organization of Interleukin-6 and Interleukin-11 α-receptors.

Authors:  Rebecca Nitz; Juliane Lokau; Samadhi Aparicio-Siegmund; Jürgen Scheller; Christoph Garbers
Journal:  Biochimie       Date:  2015-11-10       Impact factor: 4.079

9.  Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.

Authors:  Christoph Garbers; Wolfgang Thaiss; Gareth W Jones; Georg H Waetzig; Inken Lorenzen; Florence Guilhot; Rami Lissilaa; Walter G Ferlin; Joachim Grötzinger; Simon A Jones; Stefan Rose-John; Jürgen Scheller
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

10.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

View more
  2 in total

1.  Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.

Authors:  Jia Wei; Ling Ma; Yi-Hui Lai; Ruijie Zhang; Huameng Li; Chenglong Li; Jiayuh Lin
Journal:  J Exp Clin Cancer Res       Date:  2019-02-08

Review 2.  Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11.

Authors:  Riley D Metcalfe; Tracy L Putoczki; Michael D W Griffin
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.